Innate Pharma S.A. ADS (IPHA) Stock Forecast: StockMap's 2-Week Call
IPHA stock forecast: StockMap's model leans Underperform on Innate Pharma S.A. ADS for the two weeks after the Nov 19 close, toward IPHA trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 6 two-week windows on IPHA since Aug 21; by chance, a call on the same dates was right 58% of the time.
Innate Pharma S.A. ADS last closed at $0.94, -8.74% on the session.
Against the IVW growth benchmark the position is -6.41% over the forecast window.
Innate Pharma S.A. ADS' market cap is $105.00M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -36 (too close to call).
Where IPHA sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
45 daily calls for IPHA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
Innate Pharma S.A. ADS is classified under Health Care / Biotechnology.
StockMap tracks Innate Pharma S.A. ADS as the 272nd largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Innate Pharma S.A. ADS ranks 274th of 394 in the group, against a group median of -0.27.